GlassScriptPhysician profile
Frank Parrinello
NPI 1548238579
$1,673.62
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $998 · 2020: $492 · 2022: $19.56 · 2023: $144 · 2024: $20.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $164.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $275.18 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $235.45 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $214.73 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $196.35 | 2019-2020 | |
| Glaxosmithkline, LLC. | $123.12 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $86.17 | 2019-2020 | |
| Lilly USA, LLC | $83.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $46.48 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.08 | 2019-2020 | |
| Shire North American Group INC | $39.58 | 2019 | |
| Amarin Pharma, INC. | $37.70 | 2020 | |
| Melinta Therapeutics, LLC | $35.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $34.71 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.37 | 2019-2020 | |
| Amgen INC. | $29.27 | 2019-2023 | Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $20.37 | 2024 | Physio-Stim |
| Abbott Laboratories | $19.56 | 2022 | |
| Sanofi Pasteur INC. | $18.92 | 2020 | |
| Allergan, INC. | $18.22 | 2019 | |
| Dexcom, INC. | $16.04 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $15.55 | 2019 | |
| Dynavax Technologies Corporation | $13.68 | 2023 | Heplisav-B |
| Currax Pharmaceuticals LLC | $12.88 | 2023 | Onzetra Xsail, Contrave |
| Kaleo, INC. | $12.29 | 2020 | |
| Ironshore Pharmaceuticals INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Parrinello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.